Zhongshan Hospital (xiamen), Fudan University
Clinical trials sponsored by Zhongshan Hospital (xiamen), Fudan University, explained in plain language.
-
New oral drug could tame overactive bone marrow in rare blood cancers
Disease control Not yet recruitingThis study tests a pill called selinexor in 15 adults with chronic blood cancers (MPN) whose blood cell counts are too high. The goal is to see if selinexor can safely bring those counts down and ease symptoms. Participants take the drug once a week for up to 3 months and are fol…
Phase: PHASE2 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New oral drug chidamide tested for Hard-to-Treat bone marrow disorder
Disease control Not yet recruitingThis phase 2 trial tests the drug chidamide (Tucidinostat) in 15 people aged 60 or older with intermediate-to-high-risk myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. Participants take chidamide orally twice a week for up to 3 months. The study…
Phase: PHASE2 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …
Phase: PHASE1 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC